The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paludan, C.
Right arrow Articles by Münz, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paludan, C.
Right arrow Articles by Münz, C.
The Journal of Immunology, 2002, 169: 1593-1603.
Copyright © 2002 by The American Association of Immunologists

Epstein-Barr Nuclear Antigen 1-Specific CD4+ Th1 Cells Kill Burkitt’s Lymphoma Cells1

Casper Paludan*, Kara Bickham*, Sarah Nikiforow{dagger}, Ming L. Tsang*, Kiera Goodman*, Willem A. Hanekom*, Jean-Francois Fonteneau*, Stefan Stevanovic{ddagger} and Christian Münz2,*

* Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021; {dagger} Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520; and {ddagger} Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany

The {gamma}-herpesvirus, EBV, is reliably found in a latent state in endemic Burkitt’s lymphoma. A single EBV gene product, Epstein-Barr nuclear Ag 1 (EBNA1), is expressed at the protein level. Several mechanisms prevent immune recognition of these tumor cells, including a block in EBNA1 presentation to CD8+ killer T cells. Therefore, no EBV-specific immune response has yet been found to target Burkitt’s lymphoma. We now find that EBNA1-specific, Th1 CD4+ cytotoxic T cells recognize Burkitt’s lymphoma lines. CD4+ T cell epitopes of EBNA1 are predominantly found in the C-terminal, episome-binding domain of EBNA1, and ~0.5% of peripheral blood CD4+ T cells are specific for EBNA1. Therefore, adaptive immunity can be directed against Burkitt’s lymphoma, and perhaps this role for CD4+ Th1 cells extends to other tumors that escape MHC class I presentation.




This article has been cited by other articles:


Home page
J. Virol.Home page
N. Zheng, M. Fujiwara, T. Ueno, S. Oka, and M. Takiguchi
Strong Ability of Nef-Specific CD4+ Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4+ T Cells and Macrophages
J. Virol., August 1, 2009; 83(15): 7668 - 7677.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. A. Stuller and E. Flano
CD4 T Cells Mediate Killing during Persistent Gammaherpesvirus 68 Infection
J. Virol., May 1, 2009; 83(9): 4700 - 4703.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Gurer, T. Strowig, F. Brilot, M. Pack, C. Trumpfheller, F. Arrey, C. G. Park, R. M. Steinman, and C. Munz
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
Blood, August 15, 2008; 112(4): 1231 - 1239.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. A. Haigh, X. Lin, H. Jia, E. P. Hui, A. T. C. Chan, A. B. Rickinson, and G. S. Taylor
EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines
J. Immunol., February 1, 2008; 180(3): 1643 - 1654.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. D. Lunemann, T. Kamradt, R. Martin, and C. Munz
Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?
J. Virol., July 1, 2007; 81(13): 6777 - 6784.
[Full Text] [PDF]


Home page
J. Gen. Virol.Home page
Y. Ito, A. Demachi-Okamura, R. Ohta, Y. Akatsuka, K. Nishida, K. Tsujimura, Y. Morishima, T. Takahashi, and K. Kuzushima
Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells
J. Gen. Virol., March 1, 2007; 88(3): 770 - 780.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
S. Dillon, T. Sasagawa, A. Crawford, J. Prestidge, M. K. Inder, J. Jerram, A. A. Mercer, and M. Hibma
Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2
J. Gen. Virol., March 1, 2007; 88(3): 803 - 813.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. F. Zheng, L. L. Ma, G. J. Jones, M. J. Gill, A. M. Krensky, P. Kubes, and C. H. Mody
Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients
Blood, March 1, 2007; 109(5): 2049 - 2057.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. N. Heller, J. Upshaw, B. Seyoum, H. Zebroski, and C. Munz
Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers
Blood, February 1, 2007; 109(3): 1138 - 1146.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. S. Taylor, H. M. Long, T. A. Haigh, M. Larsen, J. Brooks, and A. B. Rickinson
A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+ T Cells
J. Immunol., September 15, 2006; 177(6): 3746 - 3756.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. W. Tsang, X. Lin, N. H. Gudgeon, G. S. Taylor, H. Jia, E. P. Hui, A. T. C. Chan, C. K. Lin, and A. B. Rickinson
CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes.
J. Virol., August 1, 2006; 80(16): 8263 - 8266.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
J. D. Lunemann, N. Edwards, P. A. Muraro, S. Hayashi, J. I. Cohen, C. Munz, and R. Martin
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis
Brain, June 1, 2006; 129(6): 1493 - 1506.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
D. Adhikary, U. Behrends, A. Moosmann, K. Witter, G. W. Bornkamm, and J. Mautner
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins
J. Exp. Med., April 17, 2006; 203(4): 995 - 1006.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. N. Heller, C. Gurer, and C. Munz
Virus-specific CD4+ T cells: ready for direct attack
J. Exp. Med., April 17, 2006; 203(4): 805 - 808.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Landais, X. Saulquin, M. Bonneville, and E. Houssaint
Long-Term MHC Class II Presentation of the EBV Lytic Protein BHRF1 by EBV Latently Infected B Cells following Capture of BHRF1 Antigen
J. Immunol., December 15, 2005; 175(12): 7939 - 7946.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Piriou, K. van Dort, N. M. Nanlohy, M. H. J. van Oers, F. Miedema, and D. van Baarle
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma
Blood, November 1, 2005; 106(9): 3166 - 3174.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
N. H. Gudgeon, G. S. Taylor, H. M. Long, T. A. Haigh, and A. B. Rickinson
Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity
J. Virol., May 1, 2005; 79(9): 5477 - 5488.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. S. Voo, G. Peng, Z. Guo, T. Fu, Y. Li, L. Frappier, and R.-F. Wang
Functional Characterization of EBV-Encoded Nuclear Antigen 1-Specific CD4+ Helper and Regulatory T Cells Elicited by In vitro Peptide Stimulation
Cancer Res., February 15, 2005; 65(4): 1577 - 1586.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
C. Paludan, D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Munz
Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy
Science, January 28, 2005; 307(5709): 593 - 596.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Ferlazzo, M. Pack, D. Thomas, C. Paludan, D. Schmid, T. Strowig, G. Bougras, W. A. Muller, L. Moretta, and C. Munz
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs
PNAS, November 23, 2004; 101(47): 16606 - 16611.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
R. L. Sparks-Thissen, D. C. Braaten, S. Kreher, S. H. Speck, and H. W. Virgin IV
An Optimized CD4 T-Cell Response Can Control Productive and Latent Gammaherpesvirus Infection
J. Virol., July 1, 2004; 78(13): 6827 - 6835.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. Munz
Epstein-Barr Virus Nuclear Antigen 1: from Immunologically Invisible to a Promising T Cell Target
J. Exp. Med., May 17, 2004; 199(10): 1301 - 1304.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. S. Voo, T. Fu, H. Y. Wang, J. Tellam, H. E. Heslop, M. K. Brenner, C. M. Rooney, and R.-F. Wang
Evidence for the Presentation of Major Histocompatibility Complex Class I-restricted Epstein-Barr Virus Nuclear Antigen 1 Peptides to CD8+ T Lymphocytes
J. Exp. Med., February 17, 2004; 199(4): 459 - 470.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Landais, X. Saulquin, E. Scotet, L. Trautmann, M.-A. Peyrat, J. L. Yates, W. W. Kwok, M. Bonneville, and E. Houssaint
Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1
Blood, February 15, 2004; 103(4): 1408 - 1416.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. S. Taylor, T. A. Haigh, N. H. Gudgeon, R. J. Phelps, S. P. Lee, N. M. Steven, and A. B. Rickinson
Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma
J. Virol., January 15, 2004; 78(2): 768 - 778.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Kang, T. Quan, H. Nolasco, S.-H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft
Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus
J. Immunol., January 15, 2004; 172(2): 1287 - 1294.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. Bickham, K. Goodman, C. Paludan, S. Nikiforow, M. L. Tsang, R. M. Steinman, and C. Munz
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
J. Exp. Med., December 1, 2003; 198(11): 1653 - 1663.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. Nikiforow, K. Bottomly, G. Miller, and C. Munz
Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation
J. Virol., November 15, 2003; 77(22): 12088 - 12104.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. L. Precopio, J. L. Sullivan, C. Willard, M. Somasundaran, and K. Luzuriaga
Differential Kinetics and Specificity of EBV-Specific CD4+ and CD8+ T Cells During Primary Infection
J. Immunol., March 1, 2003; 170(5): 2590 - 2598.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Yanai, E. Ishii, K. Kojima, A. Hasegawa, T. Azuma, S. Hirose, N. Suga, A. Mitsudome, M. Zaitsu, Y. Ishida, et al.
Essential Roles of Perforin in Antigen-Specific Cytotoxicity Mediated by Human CD4+ T Lymphocytes: Analysis Using the Combination of Hereditary Perforin-Deficient Effector Cells and Fas-Deficient Target Cells
J. Immunol., February 15, 2003; 170(4): 2205 - 2213.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. S. Voo, T. Fu, H. E. Heslop, M. K. Brenner, C. M. Rooney, and R.-F. Wang
Identification of HLA-DP3-restricted Peptides from EBNA1 Recognized by CD4+ T Cells
Cancer Res., December 15, 2002; 62(24): 7195 - 7199.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.